Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland.
As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of personalised medicine as it enables tests for specific cancer cells and means doctors can ensure the right treatment is administered to the patient.
Following the release of Angle’s financial results Newland reflects on what he calls “an incredible year” and he also discusses first commercial sales, a stream of ‘excellent published evidence’ from third parties and the start of major patient studies.
“We’ve got a 200 patient study in Europe running with four big cancer centres … and we’ve just recently announced a similar study in the United States,” he added.
Newland says these are substantial trials and, depending upon patient accrual, he expects results from the European study by the end of this calendar year with the US results following a few months after that.